SIRT2 Inhibitor, AGK2 is a reversible inhibitor of sirtuin 2 (SIRT2), a histone deacetylase enzyme. Inhibition of SIRT2 has been correlated to protection against dopaminergic cell death in Parkinson's disease models, and is also shown to rescue cells from toxicity conferred by alpha-synuclein expression. SIRT2 Inhibitor, AGK2 has little activity against SIRT1 and SIRT3 (IC50 >50 μM).
1. Auluck, Pavan K., et al., 2002. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science (New York, N.Y.). 295(5556): 865-8. PMID: 11823645
2. Outeiro, Tiago Fleming., et al., 2007. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science (New York, N.Y.). 317(5837): 516-9. PMID: 17588900
See how others have used SIRT2 Inhibitor, AGK2. Click on the entry to view the PubMed entry .
PMID: # 26022124 Binker, MG. et al. 2015. Biochemical and biophysical research communications. 463: 329-35.
PMID: # 20543840 Zhao, Y. et al. 2010. Nat. Cell Biol. 12: 665-675.
PMID: # 17588900 Outeiro, TF. et al. 2007. Science. 317: 516-519.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.